Trial Profile
Induction Therapy With Gefitinib Followed by Chemotherapy With Docetaxel and Cisplatin and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NeoIntercal
- 16 Aug 2017 Status changed from recruiting to discontinued.
- 17 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 03 Oct 2015 Planned number of patients changed from 21 to 49, as reported by European Clinical Trials Database.